News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Earle Burgess: Bipolar androgen therapy for advanced prostate cancer
Photo from Earle Burgess/LinkedIn
Jul 24, 2024, 13:13

Earle Burgess: Bipolar androgen therapy for advanced prostate cancer

Earle Burgess, Genitourinary Medical Oncologist, Atrium Health Levine Cancer Institute, shared on LinkedIn:

“Bipolar androgen therapy (BAT) for advanced prostate cancer: I am an advocate in the appropriate patient setting based on the TRANSFORMER study.

TRANSFORMER results and protocol.
Unfortunately we don’t know in advance which patients are most likely to benefit from using BAT.

Data presented from the TRANSFORMER study at ASCO24 suggest patients whose tumors contain an androgen receptor (AR) gene alteration may be the group most likely to benefit from BAT.

‘TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer‘ | Journal of Clinical Oncology

Authors: Samuel R Denmeade, Hao Wang, Neeraj Agarwal, David C Smith, Michael T Schweizer, Mark N Stein, Vasileios Assikis, Przemyslaw W Twardowski, Thomas W Flaig, Russell Z Szmulewitz, Jeffrey M Holzbeierlein, Ralph J Hauke, Guru Sonpavde, Jorge A Garcia, Arif Hussain, Oliver Sartor, Shifeng Mao, Harry Cao, Wei Fu, Ting Wang, Rehab Abdallah, Su Jin Lim, Vanessa Bolejack, Channing J Paller, Michael A Carducci, Mark C Markowski, Mario A Eisenberger, Emmanuel S Antonarakis.”

Earle Burgess

Source: Earle Burgess/LinkedIn

Arif Hussain ASCO24 cancer Channing J Paller David C Smith Earle Burgess Emmanuel S Antonarakis Guru Sonpavde Hao Wang Harry Cao Jeffrey M Holzbeierlein Jorge A Garcia Mario A Eisenberger Mark C Markowski Mark N. Stein metastatic prostate cancer Michael A Carducci Michael T Schweizer Neeraj Agarwal Oliver Sartor OncoDaily Oncology Przemyslaw W Twardowski Ralph J Hauke Rehab Abdallah Russell Z Szmulewitz Samuel R Denmeade Shifeng Mao Su Jin Lim Thomas W Flaig Ting Wang Vanessa Bolejack Vasileios Assikis Wei Fu
Special Coverage
Insight
Nov 15, 2024, 14:00
Myeloma Paper of the Day, November 15th, suggested by Robert Orlowski
Insight
Nov 15, 2024, 13:56
Article of the Week, Suggested by the BPDCN International Registry
Blog
Nov 15, 2024, 12:58
Herbert Loong: Kicking off the CTOS2024 with Hayden Snow
Career
Nov 15, 2024, 12:53
Jasmine Kamboj - Candidate for ASCO Nominating Committee
Insight
Nov 15, 2024, 12:51
Anand Patel: Proud to highlight 3 abstracts at ASH24
Blog
Nov 15, 2024, 12:47
Rana McKay: Surgical castration allows access to abiraterone to Brazilians with mPC
Blog
Nov 15, 2024, 12:45
Rana McKay: Integration of HSD3B1 into germline testing and clinical trials in Prostate Cancer
Opinion
Nov 15, 2024, 12:42
Rana McKay: Updates in prostate cancer treatments on Community Think Tank
Blog
Nov 15, 2024, 12:26
Sami (Papacek) Mansfield: Rising Pancreatic Cancer Rates in Younger Adults
Insight
Nov 15, 2024, 12:21
Ahmed Abbass: Managing Cholangiocarcinoma with Precision Oncology Approach
Blog
Nov 15, 2024, 12:18
Erman Akkus: No OS benefit from Preoperative and perioperative chemotherapy for Resectable Gastric Cancer
Insight
Nov 15, 2024, 12:02
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Bladder Cancer